Cue Biopharma, Inc. (NASDAQ:CUE – Get Free Report) insider Sumita Ray sold 1,844 shares of the stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $28.05, for a total value of $51,724.20. Following the transaction, the insider owned 116,701 shares of the company’s stock, valued at approximately $3,273,463.05. The trade was a 1.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Sumita Ray also recently made the following trade(s):
- On Thursday, August 13th, Sumita Ray sold 8,829 shares of Cue Biopharma stock. The stock was sold at an average price of $30.09, for a total value of $265,664.61.
Cue Biopharma Stock Up 0.4%
Shares of CUE opened at $18.67 on Friday. Cue Biopharma, Inc. has a twelve month low of $4.97 and a twelve month high of $45.50. The company has a 50 day moving average of $27.57 and a 200-day moving average of $70.86.
Cue Biopharma (NASDAQ:CUE – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). The business had revenue of $7.88 million during the quarter, compared to analyst estimates of $3.00 million. Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 620.06%. On average, sell-side analysts predict that Cue Biopharma, Inc. will post -21.79 EPS for the current fiscal year.
Institutional Investors Weigh In On Cue Biopharma
Hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new position in Cue Biopharma during the second quarter worth about $1,824,000. ADAR1 Capital Management LLC acquired a new position in Cue Biopharma during the second quarter worth approximately $1,742,000. Citadel Advisors LLC raised its stake in Cue Biopharma by 301.8% in the second quarter. Citadel Advisors LLC now owns 25,633 shares of the company’s stock valued at $809,000 after buying an additional 38,333 shares during the period. Texas Capital Bank Wealth Management Services Inc bought a new stake in Cue Biopharma in the second quarter valued at approximately $722,000. Finally, Persistent Asset Partners Ltd bought a new stake in Cue Biopharma in the second quarter valued at approximately $389,000. 35.04% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research analysts recently weighed in on the stock. Weiss Ratings downgraded shares of Cue Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 27th. B. Riley Financial began coverage on shares of Cue Biopharma in a research report on Friday, September 18th. They set a “buy” rating and a $83.00 price target on the stock. Zacks Research raised shares of Cue Biopharma to a “hold” rating in a research report on Monday, September 21st. Finally, Wall Street Zen downgraded shares of Cue Biopharma from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 26th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $83.00.
About Cue Biopharma
Cue Biopharma, Inc is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s approach is based on its proprietary Immuno-STAT (Selective Targeting of Antigenic T cells) platform, which is designed to selectively activate and expand disease-specific T cells in the body while potentially reducing the broad immune activation associated with some conventional immunotherapies.
Cue Biopharma’s pipeline includes biologic product candidates intended to target cancer-associated antigens.
See Also
- Five stocks we like better than Cue Biopharma
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
